Cargando…
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumour. Patients afflicted with this disease unfortunately have a very poor prognosis, and fewer than 5% of patients survive for 5 years from the time of diagnosis. Therefore, improved therapies to treat this disease are...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112261/ https://www.ncbi.nlm.nih.gov/pubmed/21362133 http://dx.doi.org/10.1111/j.1582-4934.2011.01296.x |